Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii.

Rosenberg A, Luth MR, Winzeler EA, Behnke M, Sibley LD.

Proc Natl Acad Sci U S A. 2019 Dec 5. pii: 201914732. doi: 10.1073/pnas.1914732116. [Epub ahead of print]

PMID:
31806760
2.

High-Throughput Measurement of Microneme Secretion in Toxoplasma gondii.

Brown KM, Sibley LD, Lourido S.

Methods Mol Biol. 2020;2071:157-169. doi: 10.1007/978-1-4939-9857-9_9.

PMID:
31758452
3.

Assays for Monitoring Toxoplasma gondii Infectivity in the Laboratory Mouse.

Wang Q, Sibley LD.

Methods Mol Biol. 2020;2071:99-116. doi: 10.1007/978-1-4939-9857-9_5.

PMID:
31758448
4.

Long-Term Culture Captures Injury-Repair Cycles of Colonic Stem Cells.

Wang Y, Chiang IL, Ohara TE, Fujii S, Cheng J, Muegge BD, Ver Heul A, Han ND, Lu Q, Xiong S, Chen F, Lai CW, Janova H, Wu R, Whitehurst CE, VanDussen KL, Liu TC, Gordon JI, Sibley LD, Stappenbeck TS.

Cell. 2019 Nov 14;179(5):1144-1159.e15. doi: 10.1016/j.cell.2019.10.015. Epub 2019 Nov 7.

5.

In Vitro Culture of Cryptosporidium parvum Using Stem Cell-Derived Intestinal Epithelial Monolayers.

Wilke G, Wang Y, Ravindran S, Stappenbeck T, Witola WH, Sibley LD.

Methods Mol Biol. 2020;2052:351-372. doi: 10.1007/978-1-4939-9748-0_20.

PMID:
31452172
6.

Protozoan persister-like cells and drug treatment failure.

Barrett MP, Kyle DE, Sibley LD, Radke JB, Tarleton RL.

Nat Rev Microbiol. 2019 Oct;17(10):607-620. doi: 10.1038/s41579-019-0238-x. Epub 2019 Aug 23. Review.

PMID:
31444481
7.

Toxoplasma gondii effector TgIST blocks type I interferon signaling to promote infection.

Matta SK, Olias P, Huang Z, Wang Q, Park E, Yokoyama WM, Sibley LD.

Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17480-17491. doi: 10.1073/pnas.1904637116. Epub 2019 Aug 14.

PMID:
31413201
8.

Toxoplasma gondii infection drives conversion of NK cells into ILC1-like cells.

Park E, Patel S, Wang Q, Andhey P, Zaitsev K, Porter S, Hershey M, Bern M, Plougastel-Douglas B, Collins P, Colonna M, Murphy KM, Oltz E, Artyomov M, Sibley LD, Yokoyama WM.

Elife. 2019 Aug 8;8. pii: e47605. doi: 10.7554/eLife.47605.

9.

The secreted kinase ROP17 promotes Toxoplasma gondii dissemination by hijacking monocyte tissue migration.

Drewry LL, Jones NG, Wang Q, Onken MD, Miller MJ, Sibley LD.

Nat Microbiol. 2019 Nov;4(11):1951-1963. doi: 10.1038/s41564-019-0504-8. Epub 2019 Jul 22.

PMID:
31332383
10.

CRTAM Protects Against Intestinal Dysbiosis During Pathogenic Parasitic Infection by Enabling Th17 Maturation.

Cervantes-Barragan L, Cortez VS, Wang Q, McDonald KG, Chai JN, Di Luccia B, Gilfillan S, Hsieh CS, Newberry RD, Sibley LD, Colonna M.

Front Immunol. 2019 Jul 2;10:1423. doi: 10.3389/fimmu.2019.01423. eCollection 2019.

11.

A Stem-Cell-Derived Platform Enables Complete Cryptosporidium Development In Vitro and Genetic Tractability.

Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, Baldridge MT, VanDussen KL, Shen B, Kuhlenschmidt MS, Kuhlenschmidt TB, Witola WH, Stappenbeck TS, Sibley LD.

Cell Host Microbe. 2019 Jul 10;26(1):123-134.e8. doi: 10.1016/j.chom.2019.05.007. Epub 2019 Jun 20.

12.

The hitchhiker's guide to parasite dissemination.

Drewry LL, Sibley LD.

Cell Microbiol. 2019 Nov;21(11):e13070. doi: 10.1111/cmi.13070. Epub 2019 Jul 8.

PMID:
31219666
13.

Secretory Microneme Proteins Induce T-Cell Recall Responses in Mice Chronically Infected with Toxoplasma gondii.

Saraav I, Wang Q, Brown KM, Sibley LD.

mSphere. 2019 Feb 27;4(1). pii: e00711-18. doi: 10.1128/mSphere.00711-18.

14.

Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.

Hopper AT, Brockman A, Wise A, Gould J, Barks J, Radke JB, Sibley LD, Zou Y, Thomas S.

J Med Chem. 2019 Feb 14;62(3):1562-1576. doi: 10.1021/acs.jmedchem.8b01754. Epub 2019 Jan 24.

PMID:
30624926
15.

Essential cGMP Signaling in Toxoplasma Is Initiated by a Hybrid P-Type ATPase-Guanylate Cyclase.

Brown KM, Sibley LD.

Cell Host Microbe. 2018 Dec 12;24(6):804-816.e6. doi: 10.1016/j.chom.2018.10.015. Epub 2018 Nov 15.

PMID:
30449726
16.

WDFY4 is required for cross-presentation in response to viral and tumor antigens.

Theisen DJ, Davidson JT 4th, Briseño CG, Gargaro M, Lauron EJ, Wang Q, Desai P, Durai V, Bagadia P, Brickner JR, Beatty WL, Virgin HW, Gillanders WE, Mosammaparast N, Diamond MS, Sibley LD, Yokoyama W, Schreiber RD, Murphy TL, Murphy KM.

Science. 2018 Nov 9;362(6415):694-699. doi: 10.1126/science.aat5030.

17.

Inhibition of Nitric Oxide Production in Activated Macrophages Caused by Toxoplasma gondii Infection Occurs by Distinct Mechanisms in Different Mouse Macrophage Cell Lines.

Cabral GRA, Wang ZT, Sibley LD, DaMatta RA.

Front Microbiol. 2018 Aug 20;9:1936. doi: 10.3389/fmicb.2018.01936. eCollection 2018.

18.

NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.

Matta SK, Patten K, Wang Q, Kim BH, MacMicking JD, Sibley LD.

MBio. 2018 Aug 28;9(4). pii: e01393-18. doi: 10.1128/mBio.01393-18.

19.

High Throughput Screen Identifies Interferon γ-Dependent Inhibitors of Toxoplasma gondii Growth.

Radke JB, Carey KL, Shaw S, Metkar SR, Mulrooney C, Gale JP, Bittker JA, Hilgraf R, Comer E, Schreiber SL, Virgin HW, Perez JR, Sibley LD.

ACS Infect Dis. 2018 Oct 12;4(10):1499-1507. doi: 10.1021/acsinfecdis.8b00135. Epub 2018 Aug 28.

20.

Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Radke JB, Burrows JN, Goldberg DE, Sibley LD.

ACS Infect Dis. 2018 Aug 10;4(8):1264-1274. doi: 10.1021/acsinfecdis.8b00113. Epub 2018 Jul 25.

21.

Monoclonal Antibodies to Intracellular Stages of Cryptosporidium parvum Define Life Cycle Progression In Vitro.

Wilke G, Ravindran S, Funkhouser-Jones L, Barks J, Wang Q, VanDussen KL, Stappenbeck TS, Kuhlenschmidt TB, Kuhlenschmidt MS, Sibley LD.

mSphere. 2018 May 30;3(3). pii: e00124-18. doi: 10.1128/mSphere.00124-18. Print 2018 Jun 27.

22.

CRISPR-mediated Tagging with BirA Allows Proximity Labeling in Toxoplasma gondii.

Long S, Brown KM, Sibley LD.

Bio Protoc. 2018 Mar 20;8(6). pii: e2768. doi: 10.21769/BioProtoc.2768.

23.

Conditional Knockdown of Proteins Using Auxin-inducible Degron (AID) Fusions in Toxoplasma gondii.

Brown KM, Long S, Sibley LD.

Bio Protoc. 2018 Feb 20;8(4). pii: e2728. doi: 10.21769/BioProtoc.2728.

24.

AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse.

McFarland R, Wang ZT, Jouroukhin Y, Li Y, Mychko O, Coppens I, Xiao J, Jones-Brando L, Yolken RH, Sibley LD, Pletnikov MV.

Behav Brain Res. 2018 Jul 16;347:193-200. doi: 10.1016/j.bbr.2018.03.023. Epub 2018 Mar 16.

25.

A conserved ankyrin repeat-containing protein regulates conoid stability, motility and cell invasion in Toxoplasma gondii.

Long S, Anthony B, Drewry LL, Sibley LD.

Nat Commun. 2017 Dec 21;8(1):2236. doi: 10.1038/s41467-017-02341-2.

26.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD.

J Med Chem. 2017 Dec 28;60(24):9976-9989. doi: 10.1021/acs.jmedchem.7b01192. Epub 2017 Oct 9.

27.

Calmodulin-like proteins localized to the conoid regulate motility and cell invasion by Toxoplasma gondii.

Long S, Brown KM, Drewry LL, Anthony B, Phan IQH, Sibley LD.

PLoS Pathog. 2017 May 5;13(5):e1006379. doi: 10.1371/journal.ppat.1006379. eCollection 2017 May.

28.

Plasma Membrane Association by N-Acylation Governs PKG Function in Toxoplasma gondii.

Brown KM, Long S, Sibley LD.

MBio. 2017 May 2;8(3). pii: e00375-17. doi: 10.1128/mBio.00375-17.

29.

Toxoplasma Effectors Targeting Host Signaling and Transcription.

Hakimi MA, Olias P, Sibley LD.

Clin Microbiol Rev. 2017 Jul;30(3):615-645. doi: 10.1128/CMR.00005-17. Review.

30.

The aromatic amino acid hydroxylase genes AAH1 and AAH2 in Toxoplasma gondii contribute to transmission in the cat.

Wang ZT, Verma SK, Dubey JP, Sibley LD.

PLoS Pathog. 2017 Mar 13;13(3):e1006272. doi: 10.1371/journal.ppat.1006272. eCollection 2017 Mar.

31.

Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches.

Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L, Sibley LD, Pelloux H, Villena I, Wallon M, Montoya JG.

PLoS Negl Trop Dis. 2017 Feb 16;11(2):e0005222. doi: 10.1371/journal.pntd.0005222. eCollection 2017 Feb. No abstract available.

32.

InsP3 Signaling in Apicomplexan Parasites.

Garcia CRS, Alves E, Pereira PHS, Bartlett PJ, Thomas AP, Mikoshiba K, Plattner H, Sibley LD.

Curr Top Med Chem. 2017;17(19):2158-2165. doi: 10.2174/1568026617666170130121042. Review.

33.

Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption.

Jimah JR, Salinas ND, Sala-Rabanal M, Jones NG, Sibley LD, Nichols CG, Schlesinger PH, Tolia NH.

Elife. 2016 Dec 1;5. pii: e20621. doi: 10.7554/eLife.20621.

34.

Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii.

Shen B, Brown K, Long S, Sibley LD.

Methods Mol Biol. 2017;1498:79-103.

PMID:
27709570
35.

Secreted protein kinases regulate cyst burden during chronic toxoplasmosis.

Jones NG, Wang Q, Sibley LD.

Cell Microbiol. 2017 Feb;19(2). doi: 10.1111/cmi.12651. Epub 2016 Aug 25.

36.

Toxoplasma Effector Recruits the Mi-2/NuRD Complex to Repress STAT1 Transcription and Block IFN-γ-Dependent Gene Expression.

Olias P, Etheridge RD, Zhang Y, Holtzman MJ, Sibley LD.

Cell Host Microbe. 2016 Jul 13;20(1):72-82. doi: 10.1016/j.chom.2016.06.006.

37.

Identification of small molecule inhibitors that block the Toxoplasma gondii rhoptry kinase ROP18.

Simpson C, Jones NG, Hull-Ryde EA, Kireev D, Stashko M, Tang K, Janetka J, Wildman SA, Zuercher WJ, Schapira M, Hui R, Janzen W, Sibley LD.

ACS Infect Dis. 2016 Mar 11;2(3):194-206. Epub 2015 Dec 28.

38.

Genetic Mapping of Pathogenesis Determinants in Toxoplasma gondii.

Behnke MS, Dubey JP, Sibley LD.

Annu Rev Microbiol. 2016 Sep 8;70:63-81. doi: 10.1146/annurev-micro-091014-104353. Epub 2016 Jun 17. Review.

PMID:
27359216
39.

Functional Analysis of the Role of Toxoplasma gondii Nucleoside Triphosphate Hydrolases I and II in Acute Mouse Virulence and Immune Suppression.

Olias P, Sibley LD.

Infect Immun. 2016 Jun 23;84(7):1994-2001. doi: 10.1128/IAI.00077-16. Print 2016 Jul.

40.

Serum Albumin Stimulates Protein Kinase G-dependent Microneme Secretion in Toxoplasma gondii.

Brown KM, Lourido S, Sibley LD.

J Biol Chem. 2016 Apr 29;291(18):9554-65. doi: 10.1074/jbc.M115.700518. Epub 2016 Mar 1.

41.

Analysis of Noncanonical Calcium-Dependent Protein Kinases in Toxoplasma gondii by Targeted Gene Deletion Using CRISPR/Cas9.

Long S, Wang Q, Sibley LD.

Infect Immun. 2016 Apr 22;84(5):1262-1273. doi: 10.1128/IAI.01173-15. Print 2016 May.

42.

Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes.

Lorenzi H, Khan A, Behnke MS, Namasivayam S, Swapna LS, Hadjithomas M, Karamycheva S, Pinney D, Brunk BP, Ajioka JW, Ajzenberg D, Boothroyd JC, Boyle JP, Dardé ML, Diaz-Miranda MA, Dubey JP, Fritz HM, Gennari SM, Gregory BD, Kim K, Saeij JP, Su C, White MW, Zhu XQ, Howe DK, Rosenthal BM, Grigg ME, Parkinson J, Liu L, Kissinger JC, Roos DS, Sibley LD.

Nat Commun. 2016 Jan 7;7:10147. doi: 10.1038/ncomms10147.

43.

Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.

Kuhlenschmidt TB, Rutaganira FU, Long S, Tang K, Shokat KM, Kuhlenschmidt MS, Sibley LD.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):570-9. doi: 10.1128/AAC.01915-15. Print 2016 Jan.

44.

A Noncanonical Autophagy Pathway Restricts Toxoplasma gondii Growth in a Strain-Specific Manner in IFN-γ-Activated Human Cells.

Selleck EM, Orchard RC, Lassen KG, Beatty WL, Xavier RJ, Levine B, Virgin HW, Sibley LD.

MBio. 2015 Sep 8;6(5):e01157-15. doi: 10.1128/mBio.01157-15.

45.

Rhoptry Proteins ROP5 and ROP18 Are Major Murine Virulence Factors in Genetically Divergent South American Strains of Toxoplasma gondii.

Behnke MS, Khan A, Lauron EJ, Jimah JR, Wang Q, Tolia NH, Sibley LD.

PLoS Genet. 2015 Aug 20;11(8):e1005434. doi: 10.1371/journal.pgen.1005434. eCollection 2015 Aug.

46.

Correction: Phosphorylation of Mouse Immunity-Related GTPase (IRG) Resistance Proteins Is an Evasion Strategy for Virulent Toxoplasma gondii.

Steinfeldt T, Könen-Waisman S, Tong L, Pawlowski N, Lamkemeyer T, Sibley LD, Hunn JP, Howard JC.

PLoS Biol. 2015 Jul 9;13(7):e1002199. doi: 10.1371/journal.pbio.1002199. eCollection 2015 Jul. No abstract available.

47.

Reply to "reproducing increased dopamine with infection to evaluate the role of parasite-encoded tyrosine hydroxylase activity".

Wang ZT, Sibley LD.

Infect Immun. 2015 Aug;83(8):3336-7. doi: 10.1128/IAI.00642-15. No abstract available.

48.

Toxoplasma Actin Is Required for Efficient Host Cell Invasion.

Drewry LL, Sibley LD.

MBio. 2015 Jun 16;6(3):e00557. doi: 10.1128/mBio.00557-15.

49.

Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.

Hui R, El Bakkouri M, Sibley LD.

Trends Pharmacol Sci. 2015 Jul;36(7):452-60. doi: 10.1016/j.tips.2015.04.011. Epub 2015 May 20. Review.

50.

REDHORSE-REcombination and Double crossover detection in Haploid Organisms using next-geneRation SEquencing data.

Shaik JS, Khan A, Beverley SM, Sibley LD.

BMC Genomics. 2015 Feb 26;16:133. doi: 10.1186/s12864-015-1309-7.

Supplemental Content

Loading ...
Support Center